Ratings Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-04-22 pm EDT			5-day change	1st Jan Change
105.51 ^USD	+1.13%		-0.93%	+14.23%

Apr. 21	Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study	MT
Apr. 21	Gilead Sciences Sees Positive Results in Phase 3 Study of Aggressive Breast Cancer	DJ

Summary: Gilead Sciences, Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Gilead Sciences, Inc.

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Gilead Sciences, Inc.

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings Chart: Gilead Sciences, Inc.

Source: Surperformance

ESG chart: Gilead Sciences, Inc.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals	Valuation	Revisions of Fundamental Estimates	Capi.($)
	GILEAD SCIENCES, INC.				132B
	ELI LILLY AND COMPANY				743B
	JOHNSON & JOHNSON				380B
	ABBVIE INC.				307B
	NOVO NORDISK A/S				266B
	ROCHE HOLDING AG				251B
	NOVARTIS AG				212B
	ASTRAZENECA PLC				210B
	MERCK & CO., INC.				199B
	AMGEN INC.				150B
	Average				285.02B
	Weighted average by Cap.

See all sector ratings

Investor

Trader

ESG MSCI

AAA

Financials

Sales growth

EPS Growth

Profitability

Net margin

Financial Health

Valuation

P/E ratio

EV/REVENUE

EV/EBITDA

PBR

Yield

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analysts' recommendations

4m Revision of opinion

Potential Price Target

4m Target Price Revision

12m Target Price Revision

Business Predictability

Earnings quality

Analyst Coverag

Divergence of analysts' recommendations

Divergence of Target Price

Divergence of analysts' opinions

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes